Title |
A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, February 2013
|
DOI | 10.1186/1745-6215-14-46 |
Pubmed ID | |
Authors |
E Marc Jolicœur, Shmuel Banai, Timothy D Henry, Marc Schwartz, Serge Doucet, Christopher J White, Elazer Edelman, Stefan Verheye |
Abstract |
A growing population of patients lives with severe coronary artery disease not amenable to coronary revascularization and with refractory angina despite optimal medical therapy. Percutaneous reduction of the coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to promote a transcollateral redistribution of coronary artery in-flow from nonischemic to ischemic subendocardial territories. A first-in-man study has demonstrated that the percutaneous reduction of the coronary sinus can be performed safely in such patients. The COSIRA trial seeks to assess whether a percutaneous reduction of the coronary sinus can improve the symptoms of refractory angina in patients with limited revascularization options. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Egypt | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 96 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 13% |
Researcher | 12 | 13% |
Student > Doctoral Student | 11 | 11% |
Student > Master | 10 | 10% |
Student > Postgraduate | 9 | 9% |
Other | 17 | 18% |
Unknown | 25 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 43 | 45% |
Psychology | 7 | 7% |
Social Sciences | 4 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 7 | 7% |
Unknown | 30 | 31% |